Helft G, Choktron S, Beygui F, Le Feuvre C, Elalamy I, Metzger J P, Vacheron A, Samama M M
Clinique de Cardiologie, Hôpital Necker, Paris, France.
Cathet Cardiovasc Diagn. 1998 Nov;45(3):329-31. doi: 10.1002/(sici)1097-0304(199811)45:3<329::aid-ccd26>3.0.co;2-q.
The aim of this study was to compare the activated clotting time (ACT) obtained with the Hemochron device and the Heparin Management Test (HMT) on a new automated whole-blood coagulometer, the Thrombolytic Assessment System, in patients undergoing angioplasty. Fifty patients undergoing balloon angioplasty were prospectively enrolled. The mean ACT after a 10,000 unit bolus of heparin was 283 +/- 39 sec at the end of the procedure. The mean HMT after 10,000 units of heparin was 286 +/- 31 sec at the end of the procedure in the same patients. The correlation between the two methods was significant (r = 0.6; P < 0.01). The HMT appears to correlate well with standard values obtained with the Hemochron ACT monitor in patients undergoing percutaneous transluminal coronary angioplasty.
